Genus non-exec bulks up stake
A round-up of the biggest director deals today so far.
Professor Barry Furr, a non-executive director at the animal breeding technology group Genus, has spent £30,000 more than doubling his stake in the animal breeding company, the firm confirmed today.
He bought 5,000 shares at 600p a time and now has 8,000.
Furr, a former chief scientist for the drug giant AstraZeneca, bought his initial stake of 3,000 shares at 680p a time in October.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Genus sells breeding technology products to livestock and farmers.
Top Director Buys
Value: £61,350
Value: £30,000
Value: £24,880
Value: £14,880
Top Director Sells
Value: £410,000
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Asia and the influence of the US
September’s US interest rate cut should be good news for Asian markets. However, there is still potential volatility surrounding the US election. On the abrdn Asian Income Fund, we are responding by raising the quality of the portfolio and structural domestic themes
By MoneyWeek Published
-
Media mogul James Dolan's straight shot at the limelight
Controversial media mogul James Dolan has been hailed as a visionary for his Sphere arena in Las Vegas. But can he square the circle financially?
By Jane Lewis Published